AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- The first patient has been dosed in the intravenous monotherapy arm of the Phase 1 onCARlytics trial.
- The patient has been dosed at City of Hope, California.
- The trial targets to recruit 52 patients with metastatic or advanced solid tumours.
- The trial is planned to expand to several sites across the US.
As part of the Phase 1 onCARlytics trial, Imugene Limited (ASX: IMU) has dosed the first patient in the intravenous monotherapy arm. The OASIS trial is the first-in-class clinical trial which is focused on adults suffering from advanced or metastatic solid tumours.
The first patient with bile tract cancer has been dosed at City of Hope, California, in the US. Further sites are expected to open across the US, and 52 patients are proposed to participate in the study.
About the trial
The title of the trial is –
Goal of the study is to assess the efficacy and safety of intratumoural (IT) injection and intravenous (IV) infusion, either individually or in combination with blinatumomab.
Under the combination arm of the trial, onCARlytics will be combined with CD19 targeting bispecific monoclonal antibody blinatumomab. The company highlighted that onCARlytics has the capability to target and wipe out solid tumours, which cannot be treated solely with Blincyto®.
IMU’s shares jumped 2.27% to trade at AU$0.112 apiece at the time of writing on 15 February 2024.